SCHEMBL1629182

SCHEMBL1629182

O=S(=O)(Nc1ccccc1F)c1cc(-c2ccnn2-c2ccccc2Cl)c(O)cc1O

nearest known ligand 0.49

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.49
ACLY P53396 10/20 0.46
KDM4E B2RXH2 2/20 0.44
NR3C2 P08235 1/20 0.40
MAPK1 P28482 1/20 0.40
PTK2B Q14289 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
OXTR P30559 1/20 0.37
PTGES2 Q9H7Z7 1/20 0.37
SLC22A12 Q96S37 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1630209 0.86 HSP90AA1 (0.49) HSP90AA1ACLYKDM4ENR3C2SMN1; SMN2
SCHEMBL1630205 0.86 HSP90AA1 (0.50) HSP90AA1ACLYKDM4ENR3C2
SCHEMBL1629233 0.85 HSP90AA1 (0.48) HSP90AA1ACLYNR3C2SMN1; SMN2
SCHEMBL15049727 0.84 HSP90AA1 (0.53) HSP90AA1ACLYNR3C2PTGES2
SCHEMBL1629899 0.84 HSP90AA1 (0.48) HSP90AA1ACLYKDM4ENR3C2
SCHEMBL1630234 0.83 ALDH1A1 (0.48) ACLYSMN1; SMN2PTGES2
SCHEMBL1629228 0.82 ALDH1A1 (0.47) HSP90AA1KDM4ENR3C2
SCHEMBL1631609 0.81 HSP90AA1 (0.55) HSP90AA1KDM4ENR3C2SMN1; SMN2
SCHEMBL1629125 0.78 HSP90AA1 (0.53) HSP90AA1NR3C2SMN1; SMN2
SCHEMBL1629715 0.77 HSP90AA1 (0.52) HSP90AA1KDM4ENR3C2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776346-B1 1,5-Diphenylpyrazoles MERCK PATENT GMBH (DE) 2013-06-26 EP claimed
US-7932401-B2 Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant MERCK PATENT GMBH (DE) 2011-04-26 US claimed
US-20080085904-A1 1,5-Diphenylpyrazoles MERCK PATENT GMBH (DE) 2008-04-10 US claimed
EP-1776346-B1 1,5-Diphenylpyrazoles MERCK PATENT GMBH (DE) 2013-06-26 EP disclosed
US-7932401-B2 Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant MERCK PATENT GMBH (DE) 2011-04-26 US disclosed
US-20080085904-A1 1,5-Diphenylpyrazoles MERCK PATENT GMBH (DE) 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085904-A1 1,5-Diphenylpyrazoles HSP90AB1, HSP90AA1, HSP90AB2P HSP90AA1 2/4885ACLY 2455/4885KDM4E 3577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.